FDA Not Writing A “Breakthrough” Guidance – Yet
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The agency needs more experience making the decisions before it lays out the evidence threshold for a breakthrough designation, CDER Director Janet Woodcock says.